(Q41912528)

14 October 2017

title

Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice (English)

1 reference

14 October 2017

T Fujiwara

1

1 reference

14 October 2017

K Sakagami

series ordinal

2

1 reference

14 October 2017

K Orita

series ordinal

3

1 reference

14 October 2017

publication date

1 January 1990

1 reference

Journal of Cancer Research and Clinical Oncology

14 October 2017

published in

1 reference

14 October 2017

volume

116

1 reference

14 October 2017

issue

2

1 reference

14 October 2017

page(s)

141-148

1 reference

Cellular origins of co-stimulator (IL2) and its activity in cytotoxic T lymphocyte responses

14 October 2017

cites work

1 reference

12 December 2020

Collagen as a vehicle for drug delivery. Preliminary report

1 reference

12 December 2020

Development of an interleukin-2 slow delivery system.

1 reference

12 December 2020

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

12 December 2020

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

1 reference

12 December 2020

T-T-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2

1 reference

12 December 2020

Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen

1 reference

12 December 2020

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

12 December 2020

Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome

1 reference

12 December 2020

Generation of mouse natural killer (NK) cell activity: effect of interleukin-2 (IL-2) and interferon (IFN) on the in vivo development of natural killer cells from bone marrow (BM) progenitor cells

1 reference

12 December 2020

Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth

1 reference

12 December 2020

Complete regression of mouse hepatoma transplanted after partial hepatectomy and the immunological mechanism of such regression

1 reference

12 December 2020

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

12 December 2020

The fate of interleukin-2 after in vivo administration

1 reference

12 December 2020

Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01612668

1 reference

14 October 2017

1 reference